瑞典及丹麥憂心肌炎風險高 暫停向年輕人提供Moderna新冠疫苗
瑞典及丹麥宣佈,由於有可能會出現罕見的心血管副作用,將暫停對年輕人注射Moderna(MRNA.US)新冠疫苗。
隔夜Moderna股價下跌8.9%,盤後再跌1.3%至298.5美元。
瑞典衛生機構表示,暫停對1991年及之後出生的人士接種注射Moderna疫苗,因數據表明已接種疫苗的年輕人患上心肌炎及心包炎的風險有所增加。丹麥當局則指,已決定根據預防性原則,暫停向18歲以下人士提供Moderna疫苗。
Moderna迴應指,已得知丹麥及瑞典監管機構的決定,強調出現心肌炎或心包炎的情況罕見,而患者的病情通常是輕微。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.